Zurich Insurance Group Ltd FI Increases Stock Holdings in Stryker Corporation $SYK

Zurich Insurance Group Ltd FI boosted its position in shares of Stryker Corporation (NYSE:SYK) by 26.0% in the 1st quarter, Holdings Channel.com reports. The fund owned 237,627 shares of the medical technology company’s stock after purchasing an additional 49,083 shares during the period. Zurich Insurance Group Ltd FI’s holdings in Stryker were worth $88,457,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of SYK. Capital A Wealth Management LLC purchased a new stake in shares of Stryker in the fourth quarter worth $26,000. Goodman Advisory Group LLC purchased a new position in Stryker during the first quarter worth about $32,000. City Holding Co. raised its holdings in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 74 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in shares of Stryker during the 1st quarter valued at about $40,000. Finally, Cornerstone Planning Group LLC grew its holdings in shares of Stryker by 46.0% during the first quarter. Cornerstone Planning Group LLC now owns 127 shares of the medical technology company’s stock worth $45,000 after purchasing an additional 40 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Stryker stock opened at $393.12 on Tuesday. The firm has a fifty day simple moving average of $389.47 and a two-hundred day simple moving average of $379.58. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a market capitalization of $150.29 billion, a PE ratio of 52.07, a P/E/G ratio of 2.85 and a beta of 0.93.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. During the same period last year, the firm earned $2.81 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is presently 44.50%.

Analyst Upgrades and Downgrades

SYK has been the subject of several research analyst reports. Citigroup reiterated a “buy” rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. BTIG Research restated a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Truist Financial set a $415.00 target price on shares of Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Evercore ISI increased their target price on Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Finally, Wells Fargo & Company lifted their price target on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $430.10.

Insider Buying and Selling

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.